Hsbc Holdings PLC Increases Stock Holdings in AbbVie Inc. $ABBV

Hsbc Holdings PLC boosted its stake in AbbVie Inc. (NYSE:ABBV) by 2.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 4,064,980 shares of the company’s stock after acquiring an additional 92,544 shares during the quarter. AbbVie accounts for about 0.5% of Hsbc Holdings PLC’s portfolio, making the stock its 26th biggest holding. Hsbc Holdings PLC’s holdings in AbbVie were worth $929,583,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. Redwood Family Wealth LLC purchased a new position in AbbVie during the fourth quarter valued at $247,000. Cedarwood Wealth LLC acquired a new stake in shares of AbbVie in the fourth quarter valued at about $430,000. Storen Legacy Partners LLC purchased a new stake in shares of AbbVie during the fourth quarter worth about $247,000. Worthington Financial Partners LLC purchased a new stake in shares of AbbVie during the fourth quarter worth about $270,000. Finally, Bayban acquired a new position in shares of AbbVie during the 4th quarter worth about $845,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Trading Up 0.1%

ABBV opened at $216.63 on Friday. AbbVie Inc. has a twelve month low of $181.73 and a twelve month high of $244.81. The firm has a market capitalization of $382.74 billion, a PE ratio of 106.71, a PEG ratio of 0.66 and a beta of 0.32. The firm’s 50-day moving average price is $212.18 and its 200 day moving average price is $218.76.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. During the same quarter in the prior year, the firm earned $2.46 EPS. AbbVie’s quarterly revenue was up 12.4% on a year-over-year basis. As a group, analysts predict that AbbVie Inc. will post 14.3 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is currently 340.89%.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie is reportedly close to buying Apogee Therapeutics for about $10.9 billion, a move that could strengthen its eczema and inflammatory-disease pipeline and support longer-term growth. AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
• Positive Sentiment: AbbVie’s recent pipeline momentum, including SKINVIVE approval and promising CLL trial results, reinforces confidence in its R&D engine and diversification beyond core immunology drugs. AbbVie (ABBV) Lands New SKINVIVE Approval As CLL Trial Results Impress
• Neutral Sentiment: AbbVie announced a quarterly dividend of $1.73 per share, underscoring its strong cash generation and shareholder-return profile. AbbVie Declares Quarterly Dividend
• Neutral Sentiment: AbbVie is also highlighting its oncology strategy at ASCO 2026, but this is more of a long-term strategic update than an immediate stock catalyst. ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of oncology
• Negative Sentiment: AbbVie’s shares had recently been under pressure as the market moved higher, reflecting some near-term investor caution before the acquisition news. AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
• Negative Sentiment: AbbVie is facing ongoing litigation risk after HHS asked a court to dismiss its suit over drug-discount patients, which could create headline overhang. HHS Asks Court to Toss AbbVie Suit Over Drug Discount Patients

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Morgan Stanley raised their price target on shares of AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. DZ Bank upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 30th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a report on Monday, June 8th. William Blair restated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Finally, Bank of America raised AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price target on the stock in a research note on Thursday, April 30th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.43.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.